FDA Public Workshop to Focus on Analgesic Drug Development for Children

The FDA is holding a public workshop, “Nonprescription Analgesic/Antipyretic Drug Development in Children 2 to Less Than 12 Years of Age.” The goal of the workshop is to discuss nonprescription pain (analgesic) and fever (antipyretic) treatment options available for children 2 to less than 12 years of age, and whether additional oral nonprescription treatment options containing acetaminophen and/or nonsteroidal anti-inflammatory drugs are needed for pain, fever or both.

The workshop will be held Nov. 15, 2024, on the FDA White Oak Campus (Building 31, the Great Room) and virtually. A Zoom link will be provided to all registered attendees in a calendar invite before the meeting.

Registration is required with options for online or on-site attendance.

The workshop is co-sponsored by the Center for Drug Evaluation and Research’s Office of New Drugs, Division of Nonprescription Drugs 1, Division of Pediatrics and Maternal Health, and Maryland Center of Excellence in Regulatory Science and Innovation, an FDA-sponsored center at the University of Maryland, under the coordination of the FDA Office of Regulatory Science and Innovation. For additional details, contact the FDA Office of New Drugs public meeting support team at ONDPublicMTGSupport@fda.hhs.gov.

Based on a press release from the FDA.